RE: Increasing USA market activity8 Feb 2021 22:10
Taken from the 3rd February RNS:
The Leeds, England-based pharmaceutical company said 24 additional patients across five active US sites have been treated in part B of the study, consisting of 12 patients with renal cell carcinoma, 9 patients with non-small cell lung cancer, and 3 bladder cancer patients.
Recruitment will continue up to a total of 30 patients in each of these indications, and enrolment for the trial is expected to complete in the fourth quarter of 2021, 4d Pharma added.
I was wondering if clinical trials normally involve patients located in different countries? If the trials are successful does it mean that FDA approval would be easier, due to the trials taking place in the US?
I’ll be surprised if there’s no press activity of the back of the recent news announcements.
After the disappointing results from BPC today, it’s good to see DDDD in the green, albeit $LOAC lagged behind.